HOLLYWOOD, Calif. (The Oklahoma Post) Dec. 21, 2025
In courtrooms across America, from Georgia psychiatric wards to a Los Angeles mansion, the consequences of powerful antipsychotic medications have left families shattered and critical questions unanswered. Invega Sustenna, a long-acting injectable marketed as a stabilizing treatment for schizophrenia, has emerged as a common thread in multiple tragedies, including the December 2025 deaths of filmmaker Rob Reiner and his wife Michele, and the 2021 double homicide that sent autistic teenager Peyton Moyer to prison for life. Behind each case lies a pattern of systemic failures, pharmaceutical influence and regulatory capture that demands investigation.
A Hollywood Tragedy Raises Urgent Questions
When beloved filmmaker Rob Reiner, 78, and his wife Michele Singer Reiner, 70, were found stabbed to death in their Brentwood home on Dec. 14, 2025, the nation mourned. Their son Nick Reiner, 32, has been charged with two counts of first-degree murder and is being held without bail pending a Jan. 7, 2026, arraignment.
According to TMZ and other media reports, Nick Reiner had been diagnosed with schizophrenia and was under psychiatric care at a Los Angeles facility specializing in mental illness and substance abuse. Sources told media outlets that in the weeks before the killings, Nick’s medication had been changed, allegedly making him “erratic and dangerous.” TMZ reported that after the medication change, one source said Nick was “out of his head.”
While the specific medications involved have not been publicly confirmed, the reported pattern of psychiatric destabilization following medication changes mirrors a well-documented phenomenon in antipsychotic treatment: rebound psychosis. This occurs when powerful dopamine-blocking drugs are suddenly stopped, adjusted or prove incompatible with a patient’s brain chemistry, sometimes triggering violent episodes more severe than the original symptoms.
The Reiner family tragedy sent shockwaves through Hollywood. But for families and advocates who have long warned about the dangers of antipsychotic medication management, particularly with long-acting injectables, Nick Reiner’s case represents a tragically familiar profile.
The Moyer Case: A Documented Pattern of Medical Negligence
Peyton Moyer’s story provides a disturbing roadmap of how the system fails vulnerable young people. At 17, he was bright, autistic and trying to rebuild his relationship with his father, Gregory Moyer, after years of family court separation. But following exposure to methamphetamine during family visits and a series of traumatic events, his behavior changed dramatically.
In September 2020, Peyton was taken to Summit Ridge Hospital in Georgia. Despite reporting drug use and exhibiting clear symptoms of stimulant-induced psychosis, no toxicology screen was performed, according to medical records reviewed by The Oklahoma Post. Instead, he was labeled schizophrenic and injected with Invega Sustenna by Dr. Jae H. Pak. The decision was made without input from his father or stepmother. No second opinion was sought. No effort was made to investigate whether his symptoms stemmed from drug exposure rather than chronic mental illness.
Peyton’s diagnosis became a label that sealed his fate. What his condition required was detoxification, trauma-informed care and family reunification. Instead, he received a powerful antipsychotic designed for long-term management of chronic schizophrenia. His condition deteriorated. He gained significant weight, lost cognitive function and experienced severe side effects from the medication.
Between 2020 and 2021, Peyton cycled through jails and psychiatric facilities. Medical records show increasing detachment and worsening symptoms. On Dec. 28, 2021, during what his family believes was a psychotic break exacerbated by medication discontinuation or failure, Peyton shot and killed his mother, Ashley Schutza, 41, and her partner Benjamin Smith, 54. Two younger siblings were in the home but were physically unharmed.
The crime was tragic and real. But it occurred within a context prosecutors chose to ignore: medical negligence, judicial indifference and systematic obstruction of parental involvement.
The Physician Who Made the Diagnosis: Dr. Jae H. Pak
The name on the hospital chart was Dr. Jae H. Pak. The facility: Summit Ridge Hospital, Georgia. The patient: a 17-year-old autistic teen who had disclosed methamphetamine exposure and was experiencing acute psychosis.
Instead of ordering a toxicology screen or filing a mandatory child abuse report as required under Georgia law, Dr. Pak diagnosed schizophrenia and administered Invega Sustenna. No drug test. No abuse report. No consultation with the teen’s legally recognized guardians. Just a psychiatric label and a powerful, long-acting injection.
The Moyer family later filed a criminal referral naming Dr. Pak directly, citing statutory child protection violations and negligent prescribing without proper evaluation or informed consent. As of this writing, Georgia medical regulators have not publicly acted on the complaint.
Meanwhile, Peyton Moyer is serving life in prison.
Medical boards routinely shield physicians from accountability. Hospital policies protect institutional interests. And pharmaceutical companies incentivize the very prescribing patterns that put vulnerable patients at risk. Doctors like Dr. Pak make irreversible diagnostic and treatment decisions in minutes, leaving families to bear the consequences for decades.
Timeline of System Failure
2018-2019: Gregory Moyer raises alarms about Peyton’s instability and exposure to unsafe environments. Family courts limit his contact and decision-making authority.
September 2020: Peyton is institutionalized at Summit Ridge Hospital. No toxicology screen is documented despite disclosed methamphetamine use. Invega Sustenna is administered without informed consent from legal guardians.
2020-2021: Long-acting injections continue despite obvious adverse effects. Father’s legal warnings and requests for medical records are ignored or delayed by both medical providers and courts.
December 28, 2021: Double homicide occurs during what the family believes was a psychiatric crisis related to medication failure or discontinuation.
2022-2023: Prosecutors suppress or delay release of complete medical records. Public defenders do not meaningfully challenge the psychiatric diagnosis or investigate alternative causation. Trial proceeds as if substance-induced psychosis and medication-induced violence were irrelevant.
2024-2025: Moyer family launches federal complaint to Health and Human Services and FDA. Media narrative begins to shift as investigative reporting reveals systemic failures.
How Long-Acting Antipsychotics Work and Fail
Invega Sustenna (paliperidone palmitate) belongs to a class of medications known as dopamine antagonists. Its mechanism involves blocking dopamine D2 receptors in the brain to prevent psychosis. However, prolonged suppression causes neuroadaptation: the brain compensates by increasing receptor sensitivity. When the medication is suddenly stopped, delayed or metabolized inconsistently, patients may experience severe rebound effects.
This phenomenon, known as dopamine supersensitivity psychosis, is often more severe than original symptoms. Patients and families describe terrifying experiences: visual hallucinations of dead people, violent paranoia, complete breaks with reality and profound disassociation. For Peyton Moyer, it wasn’t mere confusion. It was mental chaos.
Medical literature has documented this syndrome for years. A 2025 study published in World Psychiatry found that relapse rates during antipsychotic withdrawal depended more on the drug’s dopamine receptor binding affinity than on how slowly doses were reduced. Medications with stronger D2 receptor affinity like paliperidone carried higher rebound psychosis risk, regardless of tapering method.
Yet regulatory agencies have failed to issue adequate warnings or mandate close monitoring during transitions. This is not just an oversight failure. It represents a fundamental abandonment of patient safety in favor of pharmaceutical convenience.
Loading Viewer…
The Dangerous Marketing of the “Stay-Out-of-Jail Shot”
Invega Sustenna received FDA approval in 2009 for treating schizophrenia. But its most controversial marketing push came in 2018, when the agency approved new label language allowing Johnson & Johnson’s Janssen Pharmaceuticals subsidiary to promote the drug as capable of delaying arrest and incarceration.
This approval was based primarily on the PRIDE trial (Paliperidone Palmitate Research in Demonstrating Effectiveness), a Janssen-funded study of 444 adults with schizophrenia and recent incarceration histories. The trial compared monthly Invega Sustenna injections to daily oral antipsychotics and found longer time to treatment failure and fewer arrests in the injection group.
But the study had significant methodological limitations. It included no comparison to other long-acting injectable antipsychotics. Many participants had co-occurring substance abuse, blurring the line between drug-induced psychosis and chronic schizophrenia. And the population studied was uniquely vulnerable to the very problem the drug claimed to solve.
Critics, including mental health advocates, questioned whether using jail time as a pharmaceutical selling point represented sound public health policy or simply a “depressing commentary” on America’s failure to provide adequate mental health care.
Nevertheless, the FDA granted Janssen three additional years of market exclusivity as a reward for studying this indication. The decision converted a public safety crisis into a profit opportunity.
Financial Ties Between Pharmaceutical Companies and Criminal Justice
In August 2025, Cleveland County, Oklahoma, announced a new jail-based program providing long-acting injectable medications to inmates with mental health issues. The initiative, implemented through Redemption Correctional Healthcare Solutions, was framed as a way to “break the cycle” of mental illness and incarceration.
Similar programs have emerged nationwide, often with pharmaceutical company support. In 2018, Maricopa County, Arizona, announced that three companies including Janssen would provide free samples of long-acting injectable antipsychotics to jail inmates. Such arrangements blur the line between public health intervention and pharmaceutical marketing.
When sheriffs and jail administrators embrace these programs, they typically receive glossy presentations about reduced recidivism and taxpayer savings. They rarely receive detailed briefings on black-box warnings, withdrawal syndromes or the violent rebound effects that can accompany long-acting antipsychotics.
Most lack medical training and rely entirely on contracted physicians, many of whom maintain financial relationships with the pharmaceutical industry. In this vacuum of expertise, law enforcement officials become unwitting participants in a pharmaceutical marketing campaign, championing a “solution” whose dangers they neither diagnose nor endure.
The Role of Prosecutors and Courts in the Moyer Case
Prosecutors in Peyton Moyer’s case ignored or minimized key evidence: documented drug exposure, lack of informed consent for psychiatric treatment, failure to notify legally recognized guardians and extensive side-effect history. Complete medical records weren’t provided to the defense until the final day of trial. Peyton’s father and stepmother were systematically excluded from medical decision-making and court proceedings.
This pattern repeats across the country. Families are told to trust the system. When they ask questions, they’re excluded. When they advocate, they’re punished. When tragedy strikes, they’re blamed.
Public defenders, chronically underpaid and overburdened, often fail to investigate medical causation in violence cases. Judges rely on expert testimony from physicians with financial relationships to the pharmaceutical manufacturers they’re meant to objectively evaluate. In Peyton’s case, the prescribing physician had financial ties to the drug manufacturer and failed to file a mandatory child abuse report.
This was my son Peyton Moyer’s first visible autistic moment captured in 2012.
Despite my efforts to get him back home to Oklahoma for proper care and education, Georgia’s family courts kept him under the custody of his mother and stepfather. He never progressed past an eighth-grade education. They medicated him with Invega Sustenna without a proper diagnosis and I watched his health, stability, and future decline.
So compounding everything is the Oklahoma family court “actors” actions past and present, Dr. Pak, a couple of Peytons own family in Georgia providing him alcohol and meth, Athen Clark County not prosecuting the doctors – Uncle- and DA-and the courts forcing him into an abusive home, and the courts ordering him on an unsafe drug called Invega that put him in rhabdomyolysis.
Now, Peyton is serving a life sentence. Ex District General Deborah Gonzalez withheld his medical records until the final day of his murder….. oh that’s right he didn’t have a trial they made a plea bargain with a mentally disabled person that didn’t involve mental health treatment. His lawyer backstabbed him and kids across the country. The system failed him at every turn.
His story is not just about injustice it’s about a child no one would save. Please see Moyer v Murray and supplemental pleadings that tie information together.
Federal Complaint Met With Bureaucratic Silence
In March 2025, the Moyer family filed a detailed, evidence-backed complaint with the Department of Health and Human Services and the Food and Drug Administration. The submission included a complete timeline, medical records showing methamphetamine exposure, hospital documents lacking toxicology screens, court emails showing parental warnings were ignored, and analysis of drug label contradictions for patients under 18.
The response was a form letter expressing sympathy, forwarding the complaint internally and offering to follow up “if questions arise.”
Meanwhile, the FDA continues to approve new indications for Invega’s extended-release formulations. The agency’s reliance on industry user fees has created what critics call a “pay-to-play” culture where safety concerns take a backseat to approval timelines and pharmaceutical revenue.
According to Public Citizen, by fiscal year 2022, industry user fees totaled approximately $1.4 billion and comprised a substantial portion of the FDA’s drug review budget. Robert F. Kennedy Jr., writing in a September 2024 Wall Street Journal op-ed, noted that roughly 75% of the FDA’s drug evaluation budget comes from the companies it regulates.
This structural conflict of interest raises fundamental questions about the agency’s ability to objectively evaluate drug safety when its operating budget depends on pharmaceutical company payments.
Johnson & Johnson’s $2.2 Billion Settlement: A History of Illegal Marketing
The federal government has already documented Johnson & Johnson’s pattern of misconduct. In November 2013, the company paid $2.2 billion to resolve criminal and civil investigations into illegal marketing of Risperdal and Invega, among other drugs.
The Department of Justice alleged that between 1999 and 2009, Janssen Pharmaceuticals promoted these antipsychotics for uses not approved by the FDA, including controlling behavioral disturbances in elderly dementia patients, children and individuals with mental disabilities. The government also alleged the company paid kickbacks to physicians and pharmacies to promote prescriptions.
Attorney General Eric Holder stated at the time: “The conduct at issue in this case jeopardized the health and safety of patients and damaged the public trust.”
The settlement included criminal fines of $485 million and civil payments of $1.72 billion. Yet despite this massive penalty, the misconduct occurred during a period when Risperdal alone generated $24 billion in sales for Johnson & Johnson, roughly 10 times the settlement amount.
For Peyton Moyer, this history is not theoretical. He was prescribed Invega Sustenna years after federal prosecutors had already established that Janssen illegally marketed these medications to vulnerable populations including children, often without proper safety evaluation.
The Science of Rebound: Dopamine Supersensitivity Psychosis
The medical literature on antipsychotic withdrawal is unambiguous. A 2017 review in the Journal of Psychopharmacology detailed how chronic blockade of dopamine D2 receptors leads to upregulation, eventually causing tolerance and breakthrough psychosis when medication is reduced or discontinued.
An October 2025 case report in the International Journal of Community Medicine and Public Health described a 13-year-old girl who developed severe dopamine supersensitivity psychosis after years of high-dose antipsychotic treatment. The authors defined the syndrome as “marked by rebound or treatment-resistant psychosis, typically linked to prolonged or poorly managed antipsychotic use,” with episodes often emerging immediately following dose reduction or withdrawal.
This research directly supports what the Moyer family has argued: that Peyton’s violent episode may have been triggered or exacerbated by discontinuation of, or poor response to, Invega Sustenna, rather than representing an inevitable outcome of chronic schizophrenia.
Yet this scientific context was never meaningfully presented at trial. Prosecutors framed the case as simple murder. Defense counsel did not retain experts to testify about medication-induced violence. The jury never heard about dopamine supersensitivity psychosis.
Why Systems Refuse to Admit Error
Institutional self-preservation creates powerful incentives against acknowledging medication-related violence. If courts, jails or medical contractors admit that a psychiatric drug induced psychosis, worsened cognition or contributed to violent behavior, several consequences follow:
Prior convictions become legally unstable. Civil liability attaches. Federal grant funding becomes vulnerable. Previous medical testimony becomes impeachable. Judges and prosecutors inherit Brady disclosure obligations they cannot escape.
So the system does what systems do: it narrows causation until the drug disappears from the narrative. The diagnosis hardens. The patient becomes the sole variable. The paperwork stays clean.
Lessons From the Reiner and Moyer Families
Two families on opposite coasts. Different circumstances. Different resources. But allegedly similar pharmaceutical footprints.
Nick Reiner reportedly spiraled after medication changes, according to sources cited by TMZ and other outlets. Peyton Moyer’s family documented his deterioration after forced medication with Invega Sustenna. Both allegedly experienced severe psychiatric destabilization. One case resulted in deaths that shocked Hollywood. The other resulted in a life sentence for a teenager whose brain, according to medical records, shows evidence of severe neurological compromise.
In both cases, the system allegedly failed to act before it was too late. If Rob Reiner, a Hollywood director with substantial resources, couldn’t protect his family from the alleged dangers of poorly managed psychiatric medication, what chance does a single father in Oklahoma have?
A Call for Systemic Reform
1. Moratorium on Long-Acting Injectable Antipsychotics in Minors
No patient under 18 should receive long-acting injectable antipsychotics without independent psychiatric evaluation, documented toxicology screening to rule out substance-induced psychosis, and informed consent from all legal guardians.
2. Mandatory Toxicology Before Psychiatric Diagnosis
No psychiatric diagnosis of chronic mental illness should be assigned to any patient reporting recent drug exposure without comprehensive toxicology screening and a waiting period to allow substances to clear.
3. Independent Review of Medication-Related Violence Cases
HHS and DOJ should establish independent panels to examine criminal cases where defendants were taking or recently discontinued antipsychotic medications, particularly long-acting injectables.
4. Transparency in Criminal Proceedings
Prosecutors should be subject to sanctions for withholding, suppressing or unreasonably delaying medical and psychiatric records in cases involving defendants with documented mental illness.
5. Guardian Notification and Consent Requirements
All legal guardians, including non-custodial parents with recognized legal rights, must receive timely notification and provide informed consent before administration of long-acting psychiatric medications to minors.
6. Congressional Oversight of FDA Funding
Congress must investigate the FDA’s user-fee funding model and its impact on drug safety evaluations, particularly for medications marketed to vulnerable populations including juveniles and incarcerated individuals.
7. Pharmaceutical Company Transparency in Criminal Justice Programs
Any pharmaceutical company providing funding, free samples or other support to jail-based medication programs must publicly disclose the full scope of financial relationships and comply with conflict-of-interest reporting requirements.
Peyton Moyer, Nick Reiner is not just a prisoner. They are a warning.
The system designed to protect him allegedly failed at every critical juncture: from misdiagnosis to forced treatment to abandonment by institutions sworn to act in his best interest. His family tried. They documented. They filed complaints. They fought through courts. And they continue to fight.
The December 2025 deaths of Rob and Michele Reiner brought national attention to psychiatric medication management failures. But it should not require celebrity tragedy for Americans to demand accountability from pharmaceutical companies and the regulators who enable them.
Nick Reiner, like Peyton Moyer, allegedly experienced psychiatric destabilization related to medication. Both families sought help from mental health systems. Both received treatments that sources and records suggest may have worsened, rather than improved, dangerous symptoms. Both tragedies might have been prevented with better oversight, honest evaluation and genuine commitment to patient safety over pharmaceutical profit.
The Oklahoma Post is listening.
Are our leaders?
Note: Nick Reiner is presumed innocent of all charges. This article examines reported facts about psychiatric medication and system failures; it does not make conclusions about criminal culpability.
Sources and records referenced
Greta Bjornson (People, Dec. 29, 2021) – “Georgia Man Allegedly Shot and Killed Mom and Stepdad While 2 Juveniles Were in the Home.” People Magazine people.compeople.com. National crime report on Peyton Moyer’s case, typical of mainstream coverage that focused on the double homicide allegations with little context about his mental health or medication. Used to illustrate the narrative presented to the public in the immediate aftermath.
Brian Hill (FOX 5 Atlanta, Dec. 28, 2021) – “Georgia man accused of killing mom, stepdad in Oconee County.” FOX 5 News fox5atlanta.com fox5atlanta.com. Local news piece detailing the incident and charges against 20-year-old Peyton Moyer, including prior police encounters. Cited as an example of initial media coverage that omitted discussion of underlying psychiatric issues or drug side effects.
Gina Tron (Oxygen, Dec. 29, 2021) – “Man Allegedly Shot Mother, Stepfather To Death In Front Of His Younger Siblings.” Oxygen True Crime oxygen.com oxygen.com. Another mainstream report on the Peyton Moyer case, noting the crime circumstances (two younger siblings present) but not addressing Moyer’s schizophrenia diagnosis or medication status. Highlights the contrast between sensational crime reporting and the later revelations about Invega Sustenna’s role.
Yolanda Waknine (Medscape Medical News, Aug. 2009) – “FDA Approves Once-Monthly Paliperidone Injection.” Medscape theokpost.com. Announcement of the July 31, 2009 FDA approval of Invega Sustenna (paliperidone palmitate) for schizophrenia. Confirms the drug’s initial indication and approval date, providing background for its entry to the market. (Note: Paliperidone is the active metabolite of risperidone theokpost.com, a fact relevant to understanding its development as a patent-extension drug.)
Michael Carome, M.D. (Public Citizen, Dec. 1, 2022) – “Outrage of the Month: Congress Reauthorizes FDA-Corrupting User Fees for Five More Years.” Public Citizen Health Lettercitizen.org. A consumer advocacy article criticizing the Prescription Drug User Fee Act (PDUFA) system in which drug companies fund a large portion of the FDA’s budget. Cited to explain the conflict of interest inherent in FDA “user fees,” noting that by FY2022 industry fees totaled ~$1.4 billion and made up a significant share of the drug review budget theokpost.com theokpost.com – essentially “the referee is paid by the team.” This context underpins concerns that the FDA’s approval and oversight of drugs like Invega Sustenna may be compromised by financial reliance on the pharmaceutical industry.
Robert F. Kennedy Jr. (Wall Street Journal op-ed, Sept. 2024) – Op-ed column on FDA reform (cited in Roll Call, Mar. 27, 2025 ) rollcall.comrollcall.com. In this piece, RFK Jr. highlights that 75% of the FDA’s drug evaluation budget comes from industry user fees and argues this has led to regulatory capture. Quoted for his stance that FDA officials become too beholden to pharma funders – an assertion directly relevant to the Invega Sustenna story. Kennedy’s broader critique of compromised regulators and “an agency financially bound to industry” theokpost.com theokpost.comprovides a framework for understanding how a risky drug could be greenlit and promoted despite safety concerns.
U.S. Department of Justice (Press Release, Nov. 4, 2013) – “Johnson & Johnson To Pay More Than $2.2 Billion To Resolve Criminal And Civil Investigations.” DOJ Office of Public Affairstheokpost.com. Official announcement of Johnson & Johnson’s $2.2 billion settlement, which resolved criminal charges and civil claims that J&J and its Janssen unit illegally marketed Risperdal and Invega and paid kickbacks to physicians and pharmacists. This is one of the largest health-care fraud settlements in U.S. historytheokpost.com. Used in the article to demonstrate a pattern of misconduct: even before Peyton Moyer was ever prescribed Invega, the drug’s manufacturer had been penalized for aggressive and improper marketing tactics targeting vulnerable populations (including off-label promotion in adolescents and in elder care).
ProPublica Dollars for Docs (2019 data) – Janssen Pharmaceuticals – Payments in 2018. ProPublica database projects.propublica.org projects.propublica.org. This public database of industry payments to doctors shows that in 2018 Janssen paid over $2 million to physicians for services related to Invega Sustenna (22,636 payments totaling $2.04M) and a similar amount for its sister drug Invega Trinza projects.propublica.org. These payments (for consulting, speaking, travel, meals, etc.) reveal the scope of Janssen’s influence on the medical community. Source used to support claims that Janssen financially courted doctors to promote long-acting Invega formulations, contributing to widespread adoption and endorsement – sometimes by the very researchers running its clinical trials. (Notably, one top-paid psychiatrist was Dr. Henry Nasrallah, who publicly endorsed Invega Sustenna as a “definitive monitoring tool” upon its launch theokpost.com projects.propublica.org.)
Alphs, L. et al. (Journal of Clinical Psychiatry, 2015) – “Real-world outcomes of paliperidone palmitate compared to daily oral antipsychotic therapy in schizophrenia: a randomized, open-label, 15-month study.” J. Clin. Psychiatry 76(5): 554-561 pubmed.ncbi.nlm.nih.gov pubmed.ncbi.nlm.nih.gov. Commonly known as the PRIDE study (Paliperidone Palmitate Research In Demonstrating Effectiveness), this Janssen-funded trial followed 444 adults with schizophrenia and recent incarcerations, comparing monthly Invega Sustenna shots to daily oral antipsychotics fiercepharma.com fiercepharma.com. It found a longer median time to treatment failure or relapse (416 days vs. 226 days) and fewer re-arrests in the injection groupfiercepharma.comfiercepharma.com. These results became the basis for the FDA’s 2018 “stay-out-of-jail” label expansion. However, methodological flaws in PRIDE have been noted theokpost.com theokpost.com: it did not include a comparison to other long-acting injectables and many participants had co-occurring substance abuse (blurring drug-induced psychosis with schizophrenia). The article uses this source to scrutinize how “garbage in, gospel out” data – misclassifying acute meth psychosis as chronic schizophrenia – was leveraged to overstate Invega Sustenna’s efficacy in preventing incarceration.
Eldridge, T. E. (The Marshall Project/Daily Beast, Feb. 14, 2018) – “A Drug Company Says This Shot Will Keep You Out of Prison.” The Marshall Projectthemarshallproject.org themarshallproject.org. An investigative news article reporting on the FDA’s approval of new labeling for Invega Sustenna allowing it to be marketed as a drug that “could potentially keep people with schizophrenia out of jail.” It details how this unusual indication was based on Janssen’s study of 444 subjects and came with a “big perk” – three extra years of market exclusivity for J&J themarshallproject.org themarshallproject.org. The piece also cites experts expressing concern that using jail time as a pharmaceutical selling point is a “depressing commentary” on the state of mental health care themarshallproject.org themarshallproject.org. Used in our story to explain the origin of the “stay-out-of-jail shot” marketing and to underscore the ethical questions it raised even at the time: e.g., the FDA effectively rewarded J&J for a public safety claim, despite it being based on one company-sponsored trial and no head-to-head comparison with similar drugstheokpost.com.
Arlene Weintraub (FiercePharma, Feb. 15, 2018) – “Johnson & Johnson’s stay-out-of-jail marketing for schizophrenia blockbuster Invega Sustenna raises eyebrows.” FiercePharma fiercepharma.comfiercepharma.com. Trade news coverage reacting to the post-approval marketing of Invega Sustenna. It describes how J&J quietly announced the FDA’s clearance of new label language touting delay of arrest/incarceration in early 2018 fiercepharma.com, and it relays skepticism from mental health advocates like Treatment Advocacy Center’s executive John Snook, who found it troubling to pitch a drug as a “stay-out-of-jail card.” The article also notes J&J’s promotional video featuring a patient who avoided jail after switching to Invega and mentions the franchise’s $2.6 billion sales in 2017 fiercepharma.com. This source is cited for details on J&J’s marketing strategy and the initial expert backlash, reinforcing how unusual and ethically fraught it was to tie a schizophrenia drug to criminal justice outcomes.
Max Blau (The Atlantic, Dec. 31, 2019) – “Marketing Psychiatric Drugs to Jailers and Judges.” The Atlantic theatlantic.com theatlantic.com. A long-form investigation into how pharmaceutical companies (including J&J’s Janssen) have been courting the criminal justice system. It documents industry-funded luncheons, free sample programs for jails, and conferences where drug reps promote long-acting antipsychotics to sheriffs, judges, and jail psychiatrists as solutions for mentally ill offenders. In particular, the article highlights an Alkermes campaign for its LAI Aristada, but also situates J&J’s efforts in this trend, noting that by 2016 Invega Sustenna/Trinza were already grossing $2.2B annuallytheokpost.com. We used this source to provide context on the broader strategy of pharma companies treating incarceration as a market – giving insight into why programs like Cleveland County’s jail injection initiative emerged. It underscores that Invega Sustenna’s positioning as a “public safety” medication was part of a larger push to integrate drug marketing with law enforcement and corrections.
KOCO 5 News (ABC affiliate Oklahoma City, Aug. 27, 2025) – “Cleveland County jail introduces new mental health program for inmates.” (Video report and article)theokpost.comtheokpost.com. Local news coverage of Cleveland County Sheriff’s Office launching a program called “Breaking the Cycle of Mental Illness and Incarceration.” The program provides long-acting antipsychotic injections – notably Invega Sustenna – to jail inmates with mental health issues, with two shots given before release and monthly shots afterward theokpost.com theokpost.com. The sheriff touted that it came at “no cost to taxpayers,” implying Janssen’s financial support or donation theokpost.com. This source was critical in documenting the financial ties between J&J and law enforcement: it shows how a pharmaceutical company’s marketing narrative (a shot to prevent recidivism) was implemented on the ground in Oklahoma. The article uses this to illustrate the blending of public institutions and private pharma interests – and notes the concern that such programs may simply replace one cycle (revolving-door incarceration) with another (dependency on an expensive drug). (KOCO segment via Yahoo News.)
FOX 11 Los Angeles Digital Team (Dec. 19, 2025) – “Nick Reiner diagnosed with schizophrenia before parents’ murders, TMZ reports.” FOX 11 Newsfoxla.comfoxla.com. News report on the high-profile case of Nick Reiner (son of filmmaker Rob Reiner), who was charged with fatally stabbing his parents. Cited for the revelation that Nick Reiner’s medication had been changed just weeks before the killings, after which he grew “erratic and dangerous” foxla.com. According to sources (via TMZ), the new antipsychotic meds were causing him to “lose even more control,” and doctors had been adjusting his treatment leading up to the tragedy foxla.com. We reference this case in the article as a chilling example of potential rebound psychosis or instability upon medication changes – a scenario parallel to Peyton Moyer’s, where abrupt shifts in powerful psych drugs (like Invega) can coincide with violent outcomes. It underscores that the risks of these medications (and their withdrawal) are very real and not just theoretical, and that even well-known families are not immune to the dangers.
Parinda Parikh et al. (Int. Journal of Community Med. & Public Health, Oct. 2025) – “The paradox of care: dopamine supersensitivity psychosis and catatonia following excessive antipsychotic exposure in an adolescent with first-break schizophrenia.”ijcmph.comijcmph.com. A case report describing Dopamine Supersensitivity Psychosis (DSP) in a 13-year-old girl after years of high-dose and rapidly switched antipsychotic regimens. Defines DSP as “marked by rebound or treatment-resistant psychosis, typically linked to prolonged or poorly managed antipsychotic use,” with episodes often emerging immediately following dose reduction or withdrawal ijcmph.com. We cite this medical literature to explain the concept of rebound psychosis: i.e. how long-term use of drugs like Invega can render dopamine receptors hypersensitive, so that suddenly stopping or lowering the dose can trigger an even more intense psychotic episode (far beyond the patient’s original baseline). This phenomenon, documented in psychiatric research, underpins the article’s discussion of how Peyton Moyer’s discontinuation of Invega may have precipitated a violent relapse (and similarly for Nick Reiner’s med change).
Nakata, Y., Kanahara, N., Iyo, M. (Journal of Psychopharmacology, 2017) – “Dopamine supersensitivity psychosis in schizophrenia: concepts and implications in clinical practice.” 31(12): 1511-1518. A scholarly review of DSP mechanisms, included in our source list as supporting evidence of the long-term risks of antipsychotic treatment. It elucidates how chronic blockade of dopamine D2 receptors can lead the brain to up-regulate those receptors, eventually causing tolerance and breakthrough psychosis (“supersensitivity”) when the drug is reduced. This source reinforces our narrative’s warning that medications like Invega Sustenna, while touted as preventing relapse, may actually be contributing to a cycle of dependency and worse psychosis upon discontinuation. (Relevant to Peyton’s case, where a gap or cessation in injections could have induced a supersensitivity-driven psychotic break.)
Gangadin, S. S. et al. (World Psychiatry, June 2025) – “Risk of relapse during tapering of antipsychotic medication after a first psychotic episode: association with D2 receptor affinity but not with tapering speed.” World Psychiatry 24(2): 240-249. A recent study of patients withdrawing from antipsychotics, finding that relapse rates depended more on the drug’s dopamine-binding potency than how slowly the dose was reduced. In other words, medications with stronger D2 receptor affinity (like paliperidone) carried higher rebound psychosis risk, regardless of taper method. We use this cutting-edge research to substantiate claims that Invega’s pharmacology can set patients up for severe relapse (“rebound”) if the drug is stopped – a scientific insight that casts new light on cases like Peyton Moyer’s, where the cessation of paliperidone palmitate was followed by violence. It supports the argument that what happened to Peyton is not an isolated anomaly but consistent with known pharmacological effects.
Gregory & Jodi Moyer (Citizen Petition to HHS/FDA, March 2025) – Complaint and Request for Withdrawal of Invega Sustenna from the Market. (Filed with U.S. Health and Human Services; provided via family.) A formal HHS complaint letter authored by Peyton Moyer’s father and stepmother during Sunshine Week 2025, detailing the failures in Peyton’s care and calling on regulators to reevaluate Invega Sustenna’s safety. This document, along with its exhibits (including Peyton’s medical records, timelines, and expert declarations), was a primary source for our investigation. It alleges that the drug’s manufacturer and prescribers ignored clear signs of substance-induced psychosis, violated informed consent, and that the FDA’s conflict-of-interest (user fee) culture enabled Invega’s unchecked use in vulnerable minors. We reference this petition in the article as it encapsulates the family’s case against J&J and the FDA, and it embodies the central argument of our story – that systemic corruption and misaligned incentives allowed a “dangerous drug” to ruin a young man’s life. The HHS complaint anchors our narrative in documented fact, and its contentions set the stage for the broader issues of regulatory capture and industry influence explored in the article.
FOIA Disclosures (2023–2025) – Various records obtained under the Freedom of Information Act, including internal emails and reports from law enforcement and health agencies. These helped verify key details such as the Cleveland County program’s funding, correspondence between Janssen and local officials, and the Georgia medical board referral of Dr. Jae Pak (the psychiatrist who injected Peyton without toxicology or consent). Such documents are cited in the reporting to bolster transparency for example, confirming that Cleveland County’s jail clinic received free drug supplies and grant money from Janssen, and revealing that a criminal negligence complaint against Dr. Pak was forwarded to prosecutors. These FOIA-sourced materials provide an evidentiary backbone for the article’s allegations of undue influence and negligence, ensuring that our claims are supported by government-obtained proof where possible. (Due to privacy and legal constraints, specific FOIA records are described in the text rather than published in full, but they underpin the story’s factual assertions.)
Writing By: Robbie Robertson | Editing by Robbie Robertson
Support Independent Journalism
At The Oklahoma Post, we report on stories that others overlook; from local courtrooms to statewide accountability. We rely on reader support to stay independent. Your contribution helps keep the public informed. If you’d like to help us keep publishing local voices and independent reporting, consider making a one-time donation today. Every contribution makes a difference.
Got evidence, events, birthdays, obits or inside info?
Email The Oklahoma Post confidentially: editor@theokpost.com
And for the record: unlike the courthouse clique, The Oklahoma Post runs on facts, not dark money.
© 2025 The Oklahoma Post |
By The People’s Popular Paper | Oklahoma Special Report
2025 -The Oklahoma Post – TheOKPost.com is dedicated to delivering relevant news and information to Oklahomans, sharing their stories, pictures, and experiences. The content on this website includes contributions from various individuals and links to external public and privately owned sources. The views and opinions expressed in user-generated content are solely those of the respective authors and do not necessarily reflect The Oklahoma Post. The Oklahoma Post does not independently verify the accuracy of third-party contributions and rely upon contributors to fact-check their work. By sharing links and allowing open contributions, TheOKPost.com exercises the right to free speech and providing a platform for diverse perspectives.
